Regenerative Medicine Insights

This large single-center study looked at outcomes when people with relapsed multiple myeloma received a second autologous hematopoietic cell transplant (autoHCT) either later in their disease course ("delayed") or as a planned salvage treatment. The team reviewed 650 patients treated from 2006–20...